JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Deschamps, A.
Right arrow Articles by Chartrand, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Deschamps, A.
Right arrow Articles by Chartrand, D.

Vol. 300, Issue 1, 112-117, January 2002

Effects of the Anticholinesterase Edrophonium on Spectral Analysis of Heart Rate and Blood Pressure Variability in Humans

Alain Deschamps, Steven B. Backman, Vera Novak, Gilles Plourde, Pierre Fiset and Daniel Chartrand

Department of Anesthesia, Royal Victoria Hospital, McGill University, Montreal, Quebec, Canada (A.D., S.B.B., G.P., P.F., D.C.); and Department of Neurology, The Ohio State University, Columbus, Ohio (V.N.).

Edrophonium, an anticholinesterase, exerts a biphasic effect on cardiovascular autonomic drive in humans (lower doses enhance; higher doses reduce). Twenty-five anesthetized, mechanically respired (10 breaths · min-1, constant tidal volume) patients were given either saline (n = 10) or edrophonium (0.01-1.0 mg · kg-1, n = 15) following surgery. ECG, radial arterial pressure, and respiratory rate were sampled at 250 Hz to obtain time series for consecutive R-R intervals (RRIs), and systolic (SBP) and diastolic blood pressure (DBP). A Wigner distribution was used for time frequency mapping of spectral powers at high (HFP, 0.15-0.5 Hz) and low (LFP, 0.0-0.05 Hz) frequency. Edrophonium produced a dose-dependent decrease in heart rate [baseline 66.8 ± 1.9 (S.E.M.) beats per minute; maximum decrease to 55.8 ± 1.4 beats per minute with 1.0 mg · kg-1, P < 0.01]. HFP of the RRI increased at low doses (0.2-0.4 mg · kg-1; maximum increase to 111.0 ± 58.2% baseline; P < 0.01) but decreased (-49.5 ± 35.5% baseline; P < 0.01) at higher (1.0 mg · kg-1) doses. Edrophonium had no effect on SBP and DBP. HFP of SBP decreased with increasing doses (maximal decrease to -26.2 ± 7.5% baseline, P < 0.01, 1.0 mg · kg-1). LFP of SBP was also decreased (-46.3 ± 10.9% baseline, P < 0.01, 1.0 mg · kg-1). Edrophonium may enhance (lower dose) or reduce (higher dose) cardiovascular autonomic drive in humans, as evidenced by the significant changes it evokes in HFP of the RRI (parasympathetic drive), and in the HFP and LFP of SBP (sympathetic drive). These observations may account for the modest autonomic side effects of edrophonium when this drug is used clinically.


0022-3565/02/3001-0112$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.